Superbugs & You

<p>Antimicrobials are the cornerstone of modern medicine, and this is especially true for patients with cystic fibrosis. People with CF rely on antibiotics for recurring and persistent infections, and with regular use, antibiotics become less and less effective in fighting these infections. Guests include Ella Balasa, (Patient Advocate), Helen Boucher, MD (Tufts Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation).</p> <p>&nbsp;</p>

<p><strong>Season 4 of Superbugs and You is here!</strong></p> <p>Episode 14:&nbsp;This year, Italy leads the Presidency of the G7. The group is united by common values in addressing global challenges, including antimicrobial resistance. This episode features Italian leaders driving transformational policy to battle AMR. Guests include Francesca Chiara, (CIDRAP ASP), Mariano Votta (Active Citizenship Network-Cittadinanzattiva), Damiano De Felice (CARB-X), and Massimo Sartelli (Global Alliance for Infections in Surgery).</p> <p>&nbsp;</p>

<p>Health officials around the world are sounding the alarm on a highly infectious bacteria causing extensively drug-resistant infections. <em>Shigella</em>, which causes the infection known as shigellosis, is a genus of bacteria that results in gastrointestinal distress that ranges from uncomfortable to deadly, in adults and children. Global surveillance efforts on<em> Shigella</em> have identified outbreaks of strains that are extensively drug-resistant across the UK, US, and parts of Europe. How is the world dealing with this new superbug?</p> <p>&nbsp;</p> <p><strong>Guests</strong></p> <p><strong>Lou Bourgeois, PhD:</strong> Johns Hopkins, Science Officer for Enteric and Diarrheal Diseases, PATH</p> <p><strong>Gauri Godbole, MBBS, MD:</strong>&nbsp;UKHSA, Consultant Microbiologist and Parasitologist, Hospital for Tropical Diseases, University College London Hospitals, NHS</p> <p><strong>Naemah Logan, MD:</strong> Medical Officer, Surveillance Epidemiologist, National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS), Centers for Disease Control and Prevention (CDC)</p> <p><strong>Louise Francois Watkins, MD:</strong> Medical Officer, NARMS, Centers for Disease Control and Prevention: CDC</p> <p>&nbsp;</p>

<p>&nbsp;</p> <p>Over the past decade, several strains (types) of <em>Salmonella typhi</em> have become resistant to multiple antibiotics. Resistant strains have been identified across the globe. However, the 2018 launch of a vaccine has slowed infections. It is estimated that TCV introduction with a catch-up campaign will avert 42.5 million cases and 506,000 deaths caused by fluoroquinolone-resistant typhoid fever, and 21.2 million cases and 342,000 deaths from multidrug-resistant typhoid fever over 10 years following introduction. This episode will cover the impact of vaccinations and the challenges to deploy effective programs.&nbsp;</p> <p>&nbsp;</p> <p><strong>Guests:</strong></p> <ul> <strong>Farah Naz Qamar </strong>-<strong> </strong>Pediatric Infectious Disease Associate Professor, The Aga Khan University, Pakistan<br> <strong>Kathy Neuzil </strong>- Director of the Center for Vaccine Development and Global Health, University of Maryland School of Medicine<br> <strong>Denise Garrett </strong>- Vice President, Applied Epidemiology, Sabin Vaccine Institute<br> <strong>Calman MacLennan </strong>- Senior Program Officer, Bacterial Vaccines, Bill and Melinda Gates Foundation </ul> <p>&nbsp;</p> <p>For more information on the impact of typhoid conjugate vaccines and AMR, check out CIDRAP-ASP's report,&nbsp;<a href="https://www.cidrap.umn.edu/antimicrobial-stewardship/cidrap-asp-report-vaccine-bridge">A Vaccine Is a Bridge: The New Era of Typhoid Prevention</a>.</p>